Partnerships Provide Global Foundation For Alvotech
Network Of Deals Gives Company’s Biosimilar Portfolio Worldwide Reach
A network of marketing deals with key players across the globe has laid the foundations for Alvotech’s biosimilars to be marketed worldwide, the company’s founder and chairman tells Generics Bulletin in an exclusive interview.
You may also be interested in...
Ahead of the first biosimilar Humira product set to launch in less than a year, In Vivo provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.
Alvotech and Fuji Pharma have extended their strategic alliance for the commercialization of Alvotech biosimilars in Japan, adding a further early-stage candidate to the list of products covered by the deal that now encompasses six biosimilars.
Alvotech ended 2021 by revealing major plans for a SPAC merger that will provide fresh impetus for the biosimilars specialist with an injection of almost $500m in funding. In the first part of an exclusive two-part interview, founder and chairman Robert Wessman tells Generics Bulletin how the firm plans to move forward following the transaction.